The European Journal of Surgical Oncology (EJSO), published by Elsevier Science Ltd, stands as a leading international journal dedicated to the field of surgical oncology. With an ISSN of 0748-7983 and an E-ISSN of 1532-2157, EJSO has been a key resource for researchers and practitioners since its inception in 1985, covering a wide spectrum of topics in advanced surgical techniques, oncology practices, and multidisciplinary approaches to cancer treatment. The journal boasts impressive rankings, being classified in the Q1 quartile for Medicine (Miscellaneous) and Surgery, and Q2 in Oncology for 2023, reflecting its high impact within the scientific community, with a Scopus ranking of #36/551 in Medicine and Surgery, placing it in the 93rd percentile. Although it does not currently offer Open Access options, EJSO remains committed to advancing the field through reliable research and innovative surgical methodologies. Its ongoing contributions are invaluable for those engaged in the continuous improvement of cancer treatment and management.

The Indian Journal of Surgical Oncology, published by SPRINGER INDIA, is a vital source of scholarly research and discourse in the fields of oncology and surgery. Since its inception in 2010, the journal has been dedicated to advancing the science and practice of surgical oncology, providing a platform for researchers, clinicians, and educators to disseminate their findings and insights. With an increasing impact factor, the journal currently ranks in the Q4 category in Oncology and Q3 category in Surgery, reflecting its growing influence in the academic community. The journal maintains a focus on high-quality research, clinical studies, and innovative surgical techniques, fostering knowledge exchange among professionals in India and beyond. Although an open access option is not provided, the journal remains an essential repository of information for anyone engaged in the rapidly evolving fields of surgical oncology. For access to groundbreaking research and updates in the discipline, the Indian Journal of Surgical Oncology continues to be an indispensable resource.

The World Journal of Surgical Oncology, published by BMC, is a leading open-access journal that has been disseminating high-quality research since 2003. With an impressive impact, it currently holds a Q2 ranking in Oncology and a Q1 ranking in Surgery for the year 2023, reflecting its significant contribution to the field. Based in the United Kingdom, this journal serves as a vital platform for researchers, clinicians, and students alike, offering comprehensive coverage on topics ranging from innovative surgical techniques to oncology treatment advancements. As part of the esteemed BMC portfolio, the journal leverages a robust editorial process to ensure the publication of impactful research articles that promote a deeper understanding and enhancement of surgical oncology practices. Its commitment to open access ensures that critical research findings are widely accessible, fostering collaboration and knowledge sharing within the global medical community. For those dedicated to advancing their expertise in surgical oncology, the World Journal of Surgical Oncology is an indispensable resource that reflects the forefront of research and clinical practice.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

The Journal of Gastrointestinal Oncology, published by AME Publishing Company, is a leading open-access journal that focuses on the complex interplay between gastroenterology and oncology. Established in 2012 and converging into a reputable academic platform through 2024, the journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and management of gastrointestinal cancers. With an ISSN of 2078-6891 and an E-ISSN of 2219-679X, this journal presents articles that are rigorously peer-reviewed, ensuring high-quality content that meets the demands of the scientific community. Despite its current categorization in the Q3 quartile for both Gastroenterology and Oncology as of 2023, it consistently strives to improve its impact and relevance, reflected in its Scopus rankings and percentile metrics. Publishing noteworthy research, reviews, and case studies, the Journal of Gastrointestinal Oncology is instrumental in addressing significant challenges in the field, making it a must-read for those dedicated to advancing knowledge and practice in gastrointestinal oncology.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.